Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-human COVID-19 antibody and preparation method thereof

A coronavirus and antibody technology, applied in antiviral immunoglobulins, chemical instruments and methods, and egg immunoglobulins, etc., can solve the problem that antibodies cannot meet actual needs, and reduce the second or multiple outbreaks of the epidemic. , the effect of reducing the number of infections and low prices

Pending Publication Date: 2020-08-25
刘会芳
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Aiming at the problem that the current human and simian anti-COVID-19 serum antibodies cannot meet the actual needs, the present invention provides an anti-human novel coronavirus pneumonia antibody

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] This embodiment provides a method for preparing an antibody against human novel coronavirus pneumonia, which specifically includes the following steps:

[0034] Step a, poultry immunization: select 20-week-old SPF chickens, and subcutaneously inject 0.5mL of new coronary pneumonia virus L subtype inactivated water seedlings through the breast muscle or neck (the virus content is 10 5 TCID 50 / mL), and immunized again every 5 days. After 4 times of immunization, the anti-new coronary pneumonia antibody in the serum was measured by indirect ELISA method. , to collect chicken blood. Afterwards, a booster immunization with inactivated oil emulsion vaccine was carried out every 15 days to maintain the level of anti-human novel coronavirus pneumonia antibody in the blood.

[0035] Step b, extraction and separation of serum antibodies: the collected chicken blood was left to stand for 0.5h, the blood coagulated, and light yellow serum appeared in the upper layer, and the mix...

Embodiment 2

[0037] This embodiment provides a method for preparing an antibody against human novel coronavirus pneumonia, which specifically includes the following steps:

[0038] Step a, poultry immunization: select 20-week-old SPF chickens and subcutaneously inject 0.75mL of inactivated water seedlings of subtype S of new coronary pneumonia virus (the virus content is 2×10 5 TCID 50 / mL), and immunized again every 1 week. After 5 times of immunization, the anti-new coronary pneumonia antibody in the serum was measured by indirect ELISA. When the OD value of the anti-new coronary pneumonia antibody in the serum was greater than 0.2 than the positive control antibody OD value , to collect chicken blood. After that, booster immunization with inactivated oil emulsion vaccine was carried out every 20 days to maintain the level of anti-human novel coronavirus pneumonia antibody in the blood.

[0039] Step b, extraction and separation of serum antibodies: the collected chicken blood was left...

Embodiment 3

[0042] This embodiment provides a method for preparing an antibody against human novel coronavirus pneumonia, which specifically includes the following steps:

[0043] Step a, poultry immunization: select 20-week-old SPF chickens, and subcutaneously inject 1mL of new coronavirus pneumonia virus L subtype + S subtype bivalent inactivated water vaccine through the breast muscle or neck (the virus content of the two strains is 10 5 TCID 50 / mL), and immunized again every 6 days. After 5 times of immunization, the anti-new coronary pneumonia antibody in the serum was measured by indirect ELISA method. When the OD value of the anti-new coronary pneumonia antibody in the serum was greater than 0.2 than the positive control antibody OD value , to collect chicken blood. Afterwards, a booster immunization with inactivated oil emulsion vaccine was carried out every 20 days to maintain the level of anti-human novel coronavirus pneumonia antibody in the blood.

[0044] Step b, extractio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of immunology and antibody preparation, and in particular to an anti-human COVID-19 antibody and a preparation method thereof. The antibody is obtained byimmunizing healthy poultry animals with COVID-19 inactivated vaccine, collecting water-soluble components in serum or yolk when the titer of the anti-COVID-19 antibody in the serum or yolk of the immunized poultry animals meets a requirement, and purifying the water-soluble components. Corresponding antibody dry powder can be obtained by carrying out spraying, freeze-drying and other treatments onan obtained product. The antibody obtained according to the preparation method can be used for treating patients in early, middle and later stages of COVID-19, can also be used for preventing the COVID-19, and can also be matched with COVID-19 vaccine for use to enhance the prevention and control effect of the COVID-19.

Description

technical field [0001] The present invention relates to the technical fields of immunology and antibody preparation, in particular to an antibody against human novel coronavirus pneumonia and a preparation method thereof. Background technique [0002] SARS-CoV-2, the pathogen of novel coronavirus pneumonia (COVID-19, Chinese abbreviation: New Coronary Pneumonia), is a different coronavirus from SARS and MARS. Similarly, there is no cross-protection among their antibodies. Compared with SARS and MARS, SARS-COV-2 is slightly less virulent, but its ability to spread through space is stronger. Studies have found that SARS-CoV-2 is mainly prevalent in L subtype and S subtype strains, among which the L subtype virus is more virulent than the S subtype, but the S subtype virus is more resistant to inactivation and is easier to spread over long distances. on spread. In actual work, medical workers and researchers have found that asymptomatic carriers (without visual symptoms such...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C07K16/02
CPCC07K16/10C07K16/02C07K2317/23
Inventor 刘会芳宋勤叶刘朋朋左广双张鹤宋辉格陈桂清智健飞王银钱王春涛朱卫霞刘军同路强袁洪兴肖娜康敏娟杨显东魏艳秋王晓波刘梦瑶王金忠高力涛赵云刚高建华武路刚朱向清刘新杰康振江米国华李风朝牛延忠吴金水杨延旭王永红
Owner 刘会芳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com